| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer | Director, 10% Owner
2 companies
Brian G Atwood is Director, 10% Owner at OPGN, with reported holdings spanning 2 companies. Brian G Atwood's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2K at current prices.
Brian G Atwood's largest disclosed position is in CERO as Director, worth about $2K.
Brian G Atwood has 15 Form 4 filings on record from May 2015 to January 2026, across 3 companies: Director at Cero Therapeutics (CERO), 2021–2026; Director, 10% Owner at Opgen (OPGN), 2015–2016; Director, 10% Owner at Veracyte (VCYT), 2015–2016.
The 27 reported transactions were 14 option or other derivative awards, 4 other transactions, 3 conversions and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $2.5M and no sales.
The only open-market purchase was 413,332 shares of OPGN at an average $6.00 on May 8, 2015, about $2.5M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 8, 2015 | OPGN Opgen Inc | Director, 10% Owner | Buy | 413,332 | $6.00 | $2,479,992.00 | +569.4% |